To achieve quality control of therapeutic proteins, it is important to compare their biological potency with their clinical effects.
To achieve quality control of therapeutic proteins, it is important to compare their biological potency with their clinical effects. 1) Therefore, an animal-based assay is preferred for measuring their bioactivity. However, the use of laboratory animals poses ethical concerns, is time consuming and requires skilled staff and sophisticated experimental facilities. Furthermore, in vivo bioassays have low precision and accuracy, and hence, there is a need for an alternative assay method to estimate in vivo bioactivity.
To date, attempts have been made to replace traditional bioassays with physicochemical techniques for potency determination of insulin and growth hormone because it is possible to design and validate manufacturing processes in the production of properly folded materials. 2, 3) Potency of these pharmaceutical preparations can be calculated using the content assay with HPLC, which quantifies the peak area of a product against that of a reference standard of known potency. The results of the HPLC assay have been shown to correlate well with those of the bioassay. 2, 3) In addition, the HPLC assay is rapid, precise and less labour intensive than the bioassay. However, for some glycoproteins, alternative assay methods using a quantitative charge-based separation technique, such as isoelectric focusing (IEF) and capillary zone electrophoresis (CZE), have been shown to be feasible for estimating in vivo bioactivity 4, 5) because negatively charged sialic acid residues are critical for in vivo bioactivity. For example, Mulders et al. 4) reported that quantitative assessment of the isoform distribution by IEF may provide a method for predicting in vivo biological potency of preparations containing recombinant human follicle-stimulating hormone (rhFSH). Close correlation between results of experimental in vivo bioactivities and IEF-predicted in vivo bioactivities suggest that the only factor affecting prediction of biological potency is the result of quantitative isoform distribution in rhFSH.
Erythropoietin (EPO) is a glycoprotein hormone that regulates the red blood cell level by stimulating maturation of erythroid precursor cells. 6) Recombinant human EPO (rhEPO) produced in Chinese hamster ovary (CHO) cells is extensively used for serve anaemia therapy. 7) EPO comprises a 165-amino acid protein with 40% of its molecular weight accounted for by carbohydrates. 8, 9) EPO contains three Nglycans located on Asn residues at positions 24, 38, and 83 and one mucin-type O-glycan located on the Ser-126 residue. The N-linked carbohydrates comprise bi-, tri-and tetraantennary oligosaccharides, which typically terminate with a negatively charged sialic acid residue. 10, 11) Because of the variable number of sialic acid residues, the product of EPO usually exists as a mixture of isoforms with different isoelectric points. Several studies have reported that sialic acid residues are critical for in vivo bioactivity of EPO. 12, 13) Isoforms having a higher sialic acid content are seen to display higher in vivo bioactivity, longer serum half-life and slower serum clearance. 14) In the present study, we tested whether quantitative analysis of the isoform distribution may be useful for estimating in vivo bioactivity of rhEPO. The obtained results indicated that the isoform profiles determined by the measurement of sialic acid content are insufficient for predicting in vivo biological potency of rhEPO.
MATERIALS AND METHODS

Sample Preparation
All rhEPO fractions used in this study were prepared from the same clone of CHO cells transfected with a plasmid-encoding human EPO. 15) rhEPO was purified from culture supernatants through a series of chro- matographic procedures, including anion-exchange chromatography, reversed-phase chromatography and gel filtration, as described previously. 9, 16) The concentration of rhEPO in each subfraction was calculated from the absorbance at 280 nm. rhEPO was detected in each subfraction as a broad smear band on a silver-stained gel after sodium dodecylsulphate-polyacrylamide gel electrophoresis (SDS-PAGE) due to the heterogeneous nature of the attached carbohydrates (data not shown). After treatment with N-glycosidase (New England BioLabs, Ipswich, MA, U.S.A.), all subfractions gave a single band at the same position in SDS-PAGE (data not shown). The purity of each subfraction was over 95% for all samples.
CZE CZE separations were performed using the P/ACE MDQ CE System (Beckman Coulter, Fullerton, CA, U.S.A.) with a UV detector. 17) A fused-silica capillary with an internal diameter of 50 mm and effective length of 30 cm (total length: 40.2 cm) was purchased from Beckman Coulter. The capillary voltage was ϩ7 kV and separation temperature was set to 25°C. For sample injection, a pressure of 0.5 psi was applied at the capillary inlet for 5 s. The running buffer contained 10 mM Tricine, 10 mM NaCl, 10 mM sodium acetate and 7 M urea (pH 5.55). Data acquisition and analysis were performed with 32 Karat software (Beckman Coulter). Isoform species in each rhEPO subfraction were assigned by comparison with the migration time of a well-characterised commercial rhEPO. The relative proportion of respective isoforms in each EPO subfraction was determined, and the sialic acid content per molecule (SA/M) was calculated as follows:
where p8, p9, p10, p11, p12, p13 and p14 show relative proportions of isoforms 8, 9, 10, 11, 12, 13 and 14, respectively, in each EPO subfraction. In Vivo Bioassay for EPO The in vivo assay was based on the measurement of immature reticulocytes in EPO-treated mice using an automatic microcell counter, as described by Hayakawa et al. 18) with some modifications. Briefly, EPO solutions were diluted to 35 and 150 ng/ml with phosphatebuffered saline containing 0.05% bovine serum albumin. Seven-to eight-week-old female mice (B6D2F1/Crlj) were injected subcutaneously with each diluted sample (0.2 ml) once a day for three consecutive days. On day 4, blood was collected from the posterior vena cava and diluted 500 times with Celluent (Sysmex, Hyogo, Japan). Three drops (ca. 100 ml) of hemolyzing reagent Quicklyzer (Sysmex) were added to 10 ml of diluted blood. After 5 min, particles were counted using the Sysmex CDA500 automated microcell counter (Sysmex) in the leukocyte mode. Activity was determined by comparing the increased particle count of each sample with that of an EPO reference standard of known biological activity, which had been calibrated against an internationally recognized human EPO standard of the World Health Organization in a parallel assay that fulfilled the pharmacopoeial requirements for assay validity. All animal experiments were performed in accordance with the guideline for animal experiments of Kyowa Hakko Kirin and approved by the committee for animal experiments.
RESULTS
Isoform Composition Analysis of rhEPO Subfractions
Eighteen rhEPO subfractions differing in their isoform content were prepared through chromatography from a conditioned medium of CHO cells expressing rhEPO. As described above, each isoform has a different net charge that depends on the number of sialic acid residues on rhEPO: the EPO molecule can have a maximum of 14 sialic acid residues since each of the three N-linked oligosaccharides can contain up to four of these residues and the single O-linked chain can contain two. The isoform distribution of each rhEPO subfraction was analyzed by CZE (Fig. 1) . The relative proportion of each isoform is summarized in Table 1 . To quantify the sialylation level, SA/M was calculated using the relative proportions of each isoform. The SA/M value of rhEPO subfractions ranged from 10.5 to 13.6.
In Vivo Bioactivity To test whether in vivo bioactivity of rhEPO subfractions correlated with the sialylation level, activity of each subfraction was determined on the basis of increased number of reticulocytes following injection into a murine model. The correlation coefficient between sialylation level and in vivo bioactivity was determined by regression analysis (Fig. 2) . The obtained value was 0.76. As described previously, [12] [13] [14] in most cases, rhEPO subfractions containing higher sialic acid content showed higher in vivo bioactivity, and bioactivity of the subfractions decreased with a decrease in the sialic acid content. However, a low correlation coefficient value (0.76) reflects the fact that some samples showed unexpected behaviours. For example, although samples k, l and m (Table 1) have similar behaviours in the isoform profile and SA/M value (11.3), bioactivity of sample l was twofold higher than that of k or m. Relationships between samples i and j and n and o showed the same tendency. These results suggest that in vivo bioactivity of rhEPO subfractions was not simply correlated with the sialylation level calculated from quantitative analysis of the isoform distribution.
DISCUSSION
In this study, rhEPO subfractions with varying proportions of isoforms were prepared by fractionation of the culture medium from rhEPO-expressing recombinant CHO cells, and the relationship between in vivo bioactivity and isoform profile of these fractions was examined. According to previous reports, [12] [13] [14] we obtained the result indicating a positive correlation between sialic acid content and in vivo bioactivity (Fig. 2) . However, the observed correlation coefficient (0.76) was much smaller than that reported for other glycoprotein hormones, such as rhFSH (0.95).
4)
As described above, major sugar units of EPO are complex-type N-linked carbohydrates comprising bi-, tri-and tetra-antennary oligosaccharides with zero, one or two Nacetyl lactosamine (LacNAc) repeats that are typically terminated with sialic acid residues. 10, 11) In the case of the fractionated sample with the same distribution pattern of asialo N-linked oligosaccharides, a linear relationship between in vivo bioactivity and sialic acid content was observed. 19) However, the low correlation between sialic acid content and in vivo bioactivity observed in the present study suggests the possibility that glycan moieties as well as sialic acid residues may have a significant impact on in vivo bioactivity of rhEPO subfractions. This is supported by previous reports indicating that the higher branching structure of N-glycan is required for in vivo bioactivity of EPO. 16, 20) This structure may reduce non-specific clearance through a mechanism such as filtration in the kidney. Furthermore, Fukuda et al. 21) showed that EPO containing longer LacNAc repeats was efficiently captured by hepatic lectin and rapidly cleared from circulation. Therefore, both branching structures and LacNAc repeats may influence bioactivity of EPO. We anticipate that rhEPO samples analysed in the present study should have different branching structures or numbers of LacNAc repeats per N-glycan, even if their sialic acid contents are almost the same.
As described above, rhFSH potency was reported to be predictable from the result of the isoform distribution. 4) rhFSH contains approximately 35% (w/w) carbohydrates, and this ratio is very close to that in rhEPO. However, they differ in their N-linked carbohydrate composition. In rhEPO all the N-linked carbohydrate units are tetra-antennary oligosaccharides, 10, 11) whereas in rhFSH half of the N-linked carbohydrate units are mono-or di-antennary oligosaccharides, 22) indicating that rhEPO has a more complex carbohydrate structure than rhFSH. This complexity may make it difficult to predict bioactivity from the sialylation level alone in rhEPO.
Manufacturing processes for biological products are often changed during the development phase and after marketing authorization. For rhEPO, it is important to maintain a similar glycosylation pattern in both existing and new products, since the carbohydrate moieties affect their biological activity. Our results reported here suggest that examination of branching structures and numbers of LacNAc repeats per Nglycan, in addition to that of the sialylation level, are important in existing and new rhEPO products after a change in the manufacturing process. Vol. 33, No. 9
Fig. 2. Relationship between in Vivo Bioactivity and Sialylation Level in EPO Subfractions
Eighteen rhEPO subfractions differing in sialylation level (a-r) were assayed with a murine model. Specific activity is shown as a percentage relative to commercial rhEPO and is plotted against SA/M.
